Article

Not Enough Cancer Drugs, Too Many Price Controls

Cancer patients face daunting challenges, including side effects of treatment, impact on family life and work disruptions. They now face another problem: shortages of vital drugs.

Imagine an oncologist talking to his patient: Everything is going well with your treatment, he says, but one of the drugs you've been receiving is unavailable. There's a substitute—sort of. Your Medicare copayment for the drug we've been using is $9. Now it will cost you $520 each time the substitute is given.

Read the full story: http://on.wsj.com/SQoOVB

Source: The Wall Street Journal

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Cathy Eng, MD, FACP, FASCO
Leigh Maria Ramos-Platt, MD
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Molly Dean, MSW, Siftwell
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo